AbbVie collected roughly $114 billion in U.S. Humira revenue before the first biosimilar cleared a path to pharmacy shelves. Allergan […]

Every brand team runs the same model. The compound patent expires on a known date. You build a 24-month revenue

The expiration date on a blockbuster drug’s primary patent is almost never the date generic competition arrives. Between that printed

Every few years, a mid-size generic manufacturer files a Paragraph IV certification against a blockbuster drug, gets sued by a

Pharmaceutical patent litigation produces more text per dollar at stake than almost any other legal domain. A single Hatch-Waxman case

The conventional wisdom in generic pharmaceuticals is seductive in its simplicity: be first, win big. File first, launch first, collect

Every commercial contract negotiation in pharmaceuticals has a clock running in the background. That clock is the patent expiry date,

The first generic filer gets the headlines. The second entrant often gets the margin. In the United States pharmaceutical market,

The pharmaceutical patent system was designed for a different drug. A small molecule, synthesized in a lab, dosed the same